PFO
CTIC

Pathstone Family Office’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Pathstone Family Office’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-278
Closed -$8K – 353
2014
Q2 		$8K Hold
278
– – 0.02% 107
2014
Q1 		$9K Buy
+278
New +$9.5K 0.02% 109

Other funds holding CTIC

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Pathstone Family Office's CTIC Position: Q3 2014 in Review

Pathstone Family Office sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q3 2014, closing a stake of 278 shares — an estimated $8K sold.

Pathstone Family Office first reported a position in CTIC in Q1 2014 and held it in 2 quarters. The position peaked at $9K in Q1 2014. 85 funds tracked by Wall St. Rank hold CTIC as of Q3 2014.

  • Pathstone Family Office reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q3 2014 after selling out during the quarter.
  • Pathstone Family Office sold 278 CTI BioPharma Corp. (DE) Common Stock shares in Q3 2014, an estimated $8K.
  • Pathstone Family Office first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2014 and held it in 2 quarters.
  • Pathstone Family Office's CTI BioPharma Corp. (DE) Common Stock position peaked at $9K in Q1 2014.
  • 85 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q3 2014.

Based on Pathstone Family Office's 13F filing for Q3 2014, filed 12 Nov 2014.